Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
John P Dubinsky
AddedMar 31, 2024
UpdatedMay 1, 2026
John P Dubinsky

John P Dubinsky

Board Member, Stifel Bank & Trust

John P Dubinsky's Career

Stifel Bank & Trust
Stifel Bank & Trust

St. Louis, MO, US

Board Member· Board
Accentia Biopharmaceuticals
Accentia Biopharmaceuticals

Tampa, FL, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

John P Dubinsky's Career

Stifel Bank & Trust
Stifel Bank & Trust
Investment FirmInvestment Firm02007St. Louis, MO, US
Board Member· Board

Leadership at Stifel Bank & Trust

Frederick O HanserFrederick O HanserBoard Member
John DubinksyJohn DubinksyBoard Member
Accentia Biopharmaceuticals
Accentia Biopharmaceuticals
Public$775k752002Tampa, FL, US
Board Member· Board

Leadership at Accentia Biopharmaceuticals

william poolewilliam pooleBoard Member
David M. SchubertDavid M. SchubertBoard Member
Garrison J HasaraGarrison J HasaraCEO

Similar to Accentia Biopharmaceuticals

Accent TherapeuticsAccent TherapeuticsLexington, MA, USDrug Developmentest. 2017Accent TherapeuticsLexington, MA, US · est. 2017

Accent Therapeutics, a NY-based biopharmaceutical company, specializes in developing inhibitory molecule drugs.

Series C · $178M69
Ascenta TherapeuticsAscenta TherapeuticsMalvern, PA, USCancer Treatmentsest. 2003Ascenta TherapeuticsMalvern, PA, US · est. 2003

Ascenta Therapeutics: A clinical-stage biopharma company innovating new cancer treatments.

Public · $87.8M75
LTZ TherapeuticsLTZ TherapeuticsSan Francisco, CA, USImmunotherapy, Therapeuticsest. 2022LTZ TherapeuticsSan Francisco, CA, US · est. 2022

LTZ: Innovating immunotherapies for cancer and diseases with unmet clinical needs.

Seed · $27M16
Axikin PharmaceuticalsAxikin PharmaceuticalsSan Diego, CA, USDrugs, Therapeuticsest. 2008Axikin PharmaceuticalsSan Diego, CA, US · est. 2008

Axikin Pharmaceuticals, Inc.: Biotech drug manufacturer specializing in respiratory disorder therapeutics.

Public · $18.5M30

John P Dubinsky's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailKen KutaragiKen KutaragiBoard Member · RakutenTakashi MitachiTakashi MitachiBoard Member · Rakuten

People Similar to John P Dubinsky

John DubinskyJohn DubinskyBoard Member · Barnes-Jewish HospitalJohn DanilovichJohn DanilovichJohn SJohn SJohn ZdanowskiJohn ZdanowskiJohn BurbankJohn Burbank